Vidhi Specialty (VIDHIING)

FairStock Score: 37/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 18.73% and ROE of 16.52% show capital is being used efficiently.
• Low debt/equity of 0.20 provides balance-sheet safety in a downturn.
• Latest quarter profit of ₹12 Cr on ₹94 Cr sales implies a healthy net margin.
• Promoter holding of 64.27% aligns management with public shareholders.

Concerns

• Sales growth is negative at -4.13% and profit growth is -1.97%, indicating no current growth engine.
• At P/E of 32.35 and P/B of 5.65, valuation leaves no room for error.
• Piotroski F-Score of 3/9 suggests weak operating/financial momentum.
• FairStock Score of 8/100 flags the stock as risky.

AI Analysis

I am drawn to good businesses bought at a sensible price, not just any business. Vidhi Specialty is a small specialty chemicals player, and the first facts are respectable: return on equity of 16.52%, return on capital of 18.73%, and debt/equity of just 0.20. Promoters own 64.27%, so their interests are largely aligned with minority shareholders. But the last year has been troubling. Sales are down 4.13% and profits down 1.97%. That is not a stampede of rising demand or pricing power. A Piotroski F-score of 3 out of 9 reinforces my caution—the financial signals are not generally those of improving business health. The market price, however, is not cautious. At ₹312.75, the stock trades at 32.35 times earnings and 5.65 times book value, while book value is only ₹55.35. So I am paying a huge premium for a business whose near-term momentum is negative. The dividend yield of 1.61% is modest compensation for that risk. In the latest quarter, Vidhi generated ₹94 Cr of sales and ₹12 Cr of profit—a decent margin but not enough to justify a ₹1,550 Cr market cap if growth stays dead. FairStock's 8/100 risk score is another warning bell; it tells me the odds are not in my favour. Ben Graham taught me that price is what you pay, value is what you get. Here, I see a financially solid but shrinking company. A specialty chemical business may have a niche, but I don't see a wide moat in these numbers, and negative growth gives me no confidence that pricing power exists. It may be a fine business, but at this price the margin of safety is missing. I would put it on a watchlist and only act after growth returns or the price falls to a level that builds in the current weakness.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer